Quick Answer
Vanda Pharmaceuticals Inc. reported Net Income of -$220.47 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$220.47M | -1066.5% |
| 2024 | -$18.90M | -853.3% |
| 2023 | $2.51M | -60.0% |
| 2022 | $6.28M | -81.1% |
| 2021 | $33.15M | +42.1% |
| 2020 | $23.34M | -79.8% |
| 2019 | $115.55M | +358.4% |
| 2018 | $25.21M | +261.9% |
| 2017 | -$15.57M | +13.6% |
| 2016 | -$18.01M | +54.8% |
| 2015 | -$39.87M | -297.5% |
| 2014 | $20.19M | +195.9% |
| 2013 | -$21.05M | +26.4% |
| 2012 | -$28.62M | -192.0% |
| 2011 | -$9.80M | -236.3% |
| 2010 | $7.19M | +120.1% |
| 2009 | -$35.86M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.59M | -324.2% | +17.0% |
| June 30, 2025 | -$27.21M | -502.2% | +7.8% |
| March 31, 2025 | -$29.49M | -611.4% | -454.0% |
| September 30, 2024 | -$5.32M | -3986.1% | -17.8% |
| June 30, 2024 | -$4.52M | -397.2% | -9.0% |
| March 31, 2024 | -$4.15M | -227.5% | -3126.3% |
| September 30, 2023 | $137.0K | -95.8% | -91.0% |
| June 30, 2023 | $1.52M | -40.9% | -53.3% |
- Vanda Pharmaceuticals Inc. showed a decrease of -1066.5% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Vanda Pharmaceuticals Inc.’s net income has declined by 514.8% (from -$35.86 million to -$220.47 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: